C.M. Bidwell & Associates’s Pacific Biosciences PACB Stock Holding History

C.M. Bidwell & Associates’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$127	Hold	96	–	–	﹤0.01%	477
2025 Q4	$180	Hold	96	–	–	﹤0.01%	479
2025 Q3	$123	Hold	96	–	–	﹤0.01%	484
2025 Q2	$119	Hold	96	–	–	﹤0.01%	443
2025 Q1	$113	Hold	96	–	–	﹤0.01%	436
2024 Q4	$176	Sell	96 -220	-70%	-$429	﹤0.01%	479
2024 Q3	$537	Hold	316	–	–	﹤0.01%	461
2024 Q2	$433	Hold	316	–	–	﹤0.01%	449
2024 Q1	$1.19K	Hold	316	–	–	﹤0.01%	418
2023 Q4	$3.1K	Hold	316	–	–	﹤0.01%	385
2023 Q3	$2.64K	Hold	316	–	–	﹤0.01%	427
2023 Q2	$4.2K	Hold	316	–	–	﹤0.01%	407
2023 Q1	$3.66K	Hold	316	–	–	﹤0.01%	410
2022 Q4	$2.58K	Buy	316 +220	+229%	+$1.9K	﹤0.01%	417
2022 Q3	$1K	Buy	+96	New	+$551	﹤0.01%	459
2022 Q2	–	Sell	-96	Closed	-$1K	–	536
2022 Q1	$1K	Buy	+96	New	+$1.1K	﹤0.01%	502

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

C.M. Bidwell & Associates's PACB Position: Q1 2026 in Review

C.M. Bidwell & Associates held its Pacific Biosciences (PACB) position steady in Q1 2026 at 96 shares worth $127. The position accounts for ﹤0.01% of the portfolio, ranked #477.

C.M. Bidwell & Associates first reported a position in PACB in Q1 2022 and has held it in 16 quarters since. The position peaked at $4.2K in Q2 2023. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

C.M. Bidwell & Associates held 96 shares of Pacific Biosciences worth $127 as of Q1 2026.
C.M. Bidwell & Associates left its Pacific Biosciences share count unchanged in Q1 2026.
Pacific Biosciences made up ﹤0.01% of C.M. Bidwell & Associates's portfolio in Q1 2026, its #477 holding.
C.M. Bidwell & Associates first reported a position in Pacific Biosciences in Q1 2022 and has held it in 16 quarters since.
C.M. Bidwell & Associates's Pacific Biosciences position peaked at $4.2K in Q2 2023.
229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on C.M. Bidwell & Associates's 13F filing for Q1 2026, filed 15 May 2026.